RxDoctor Payments Data

Tracy Fry, APRN

Family · Grove, OKNPI 1174070205

Payments from drug & device makers

$891in general payments, 2019–2025

Across 56 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$187
  • Otsuka America Pharmaceutical, Inc.$99
  • Lundbeck LLC$89
  • Novo Nordisk$60
  • Avanir Pharmaceuticals, Inc.$52
  • Takeda Pharmaceuticals U.S.A., Inc.$48
  • plus $357 from 15 others

What the payments were for

  • Food & beverage$891100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$891 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$25,154
Medicare patients
145
Services billed
1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide118$157,049
EliquisApixaban59$68,043
TrulicityDulaglutide50$63,927
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$36,652
RexultiBrexpiprazole19$29,726
OzempicSemaglutide13$26,804
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$12,122
Tresiba Flextouch U-100Insulin Degludec11$11,112
GemtesaVibegron11$10,149
JardianceEmpagliflozin11$8,987
Advair HfaFluticasone Propion/Salmeterol12$6,244
MyrbetriqMirabegron11$6,037
Albuterol Sulfate HfaAlbuterol Sulfate144$4,637
Desvenlafaxine Succinate ErDesvenlafaxine Succinate60$3,750
Gabapentin164$3,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$31$220,976168 claims
PfizerEliquis$43$68,04359 claims
GSKTrelegy Ellipta$34$36,65246 claims
Otsuka America Pharmaceutical, Inc.Rexulti$99$29,72619 claims
Novo NordiskOzempic$60$26,80413 claims
AstraZenecaBreztri Aerosphere$27$12,12213 claims
Sumitomo Pharma America, Inc.Gemtesa$14$10,14911 claims
Boehringer IngelheimJardiance$33$8,98711 claims
AbbVieSynthroid$187$84716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,026 family providers in Oklahoma.

Other family in Grove

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →